Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

Market Cap	12.45B -29.3%
Revenue (ttm)	4.03B +6.0%
Net Income	585.83M -20.2%
EPS	0.36 -18.4%
Shares Out	1.61B
PE Ratio	21.42
Forward PE	12.05
Dividend	0.10 (1.27%)
Ex-Dividend Date	Jun 9, 2026

Volume	9,172,070
Open	7.83
Previous Close	7.89
Day's Range	7.70 - 7.93
52-Week Range	7.63 - 12.27
Beta	0.40
Analysts	Strong Buy
Price Target	11.94 (+54.86%)
Earnings Date	Aug 28, 2026

About SHA:603707

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, halo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,558
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603707

Financial Performance

In 2025, SHA:603707's revenue was 3.99 billion, an increase of 1.71% compared to the previous year's 3.92 billion. Earnings were 581.54 million, a decrease of -29.61%.

Analyst Summary

According to 4 analysts, the average rating for 603707 stock is "Strong Buy." The 12-month stock price target is ¥11.94, which is an increase of 54.86% from the latest price.

Price Target

¥11.94

(54.86% upside)

Analyst Consensus: Strong Buy